MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 01-08-2026
Neogen Corporation Total Assets 2011-2026 | NEOG
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Neogen Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.44 B | 4.55 B | 4.55 B | 993 M | 920 M | 797 M | 696 M | 618 M | 528 M | 452 M | 392 M | 345 M | 291 M | 252 M | 220 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.55 B | 220 M | 1.27 B |
Quarterly Total Assets Neogen Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.36 B | 3.38 B | 3.44 B | 4.04 B | 4.05 B | 4.5 B | 4.55 B | 4.58 B | 4.6 B | 4.56 B | 4.55 B | 4.51 B | 4.56 B | 977 M | 993 M | 981 M | 968 M | 932 M | 920 M | 920 M | 846 M | 822 M | 846 M | 774 M | 751 M | 721 M | 751 M | 721 M | 660 M | 641 M | 660 M | 641 M | 581 M | 547 M | 581 M | 547 M | 487 M | 469 M | 487 M | 469 M | 426 M | 409 M | 426 M | 409 M | 366 M | 358 M | 366 M | 358 M | 320 M | 308 M | 320 M | 308 M | 270 M | 261 M | 270 M | 261 M | 234 M | 228 M | 234 M | 228 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.6 B | 228 M | 1.35 B |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
10.7 B | $ 113.95 | -0.77 % | $ 34.6 B |  USA |
 |
CareDx, Inc
CDNA
|
413 M | $ 17.3 | -2.92 % | $ 922 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M |  Britain |
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 16.4 | 0.61 % | $ 176 M |  China |
 |
Co-Diagnostics
CODX
|
24.7 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Aspira Women's Health
AWH
|
5.46 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | USA |
 |
National Research Corporation
NRC
|
135 M | $ 17.24 | -0.52 % | $ 386 M | USA |
 |
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
7.14 B | $ 168.88 | 0.33 % | $ 8.37 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
 |
Castle Biosciences
CSTL
|
531 M | $ 24.9 | 0.67 % | $ 692 M | USA |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
|
Biodesix
BDSX
|
97.2 M | $ 15.24 | -0.78 % | $ 1.98 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
26.9 B | $ 26.95 | -0.97 % | $ 20 B |  Niderland |
 |
Danaher Corporation
DHR
|
83.5 B | $ 191.24 | -0.44 % | $ 136 B | USA |
 |
DexCom
DXCM
|
6.34 B | $ 64.09 | 1.39 % | $ 25 B | USA |
 |
Fulgent Genetics
FLGT
|
1.22 B | $ 16.44 | 0.12 % | $ 497 M | USA |
 |
QIAGEN N.V.
QGEN
|
6.28 B | - | - | $ 10.6 B | Niderland |
 |
Guardant Health
GH
|
2.01 B | $ 90.19 | 0.59 % | $ 11.3 B | USA |
 |
Anixa Biosciences
ANIX
|
16.1 M | $ 2.61 | 0.77 % | $ 84.7 K | USA |
 |
Biomerica
BMRA
|
5.94 M | $ 2.13 | -2.07 % | $ 4.89 M | USA |
 |
BioNano Genomics
BNGO
|
73.6 M | $ 1.13 | -1.7 % | $ 6.15 M | USA |
 |
ICON Public Limited Company
ICLR
|
16.9 B | $ 108.32 | -1.18 % | $ 8.93 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
33.8 M | $ 1.97 | - | $ 8.72 M | USA |
 |
Illumina
ILMN
|
6.3 B | $ 127.78 | 0.03 % | $ 20.3 B | USA |
 |
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M |  Israel |
 |
Celcuity
CELC
|
467 M | $ 113.83 | -0.35 % | $ 5.32 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 275.15 | 0.21 % | $ 22.9 B | USA |
 |
Lantheus Holdings
LNTH
|
2.23 B | $ 76.09 | 0.26 % | $ 5.14 B | USA |
 |
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | USA |
 |
Medpace Holdings
MEDP
|
1.98 B | $ 497.15 | 0.23 % | $ 14.3 B | USA |
 |
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
5.86 B | - | - | $ 19.8 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 199.79 | 0.37 % | $ 22.2 B | USA |
 |
Myriad Genetics
MYGN
|
707 M | $ 4.7 | 0.64 % | $ 435 M | USA |
 |
ENDRA Life Sciences
NDRA
|
3.85 M | $ 4.74 | - | $ 3.73 M | USA |
 |
NeoGenomics
NEO
|
1.36 B | $ 8.04 | 0.25 % | $ 1.03 B | USA |
 |
Natera
NTRA
|
1.39 B | $ 206.6 | 0.84 % | $ 20.3 B | USA |
 |
Pacific Biosciences of California
PACB
|
784 M | $ 1.38 | -2.82 % | $ 414 M | USA |
 |
Precipio
PRPO
|
21.3 M | $ 25.98 | - | $ 41.7 M | USA |
 |
Personalis
PSNL
|
270 M | $ 6.38 | -3.04 % | $ 378 M | USA |
 |
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | USA |